- Home
- MAGH vs OBIO Comparison
MAGH vs OBIO Comparison
Compare MAGH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAGH | OBIO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.4M | 237.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAGH | OBIO |
|---|---|---|
| Price | $6.85 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.2M | 325.3K |
| Earning Date | 12-23-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $11,752,129.00 | $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | $7,194.11 | ★ N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $0.99 | $2.20 |
| 52 Week High | $6.94 | $6.30 |
Technical Indicators
Market Signals| Indicator | MAGH | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.07 |
| Support Level | N/A | $4.19 |
| Resistance Level | N/A | $4.69 |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 27.15 |
Price Performance
Historical ComparisonAbout MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.